论文部分内容阅读
目的：探讨低分子肝素钠（法安明）在急性脑梗死（ＡＩＳ）治疗中的有效性和安全性。方法：对入选的９８例ＡＩＳ病人随机对照研究，法安明组５６例，对照组４２例。根据ＣＳＳ对两组ＡＩＳ病人治疗前后的神经功能状况进行分析比较，同时对比观察两组病人出血性合并症及病死率发生情况。结果：法安明组总体疗效优于对照组（ Ｐ＜ ０． ０５）。在椎基底动脉（ ＶＢＡ）系统中法安明组优于对照组，疗效有显著差异（ Ｐ＜ ０． ０２５）。在安全性方面，法安明与出血性合并症及病死率与对照组无显著差异。结论：法安明治疗ＶＢＡ系统ＡＩＳ安全、有效。
Objective: To investigate the efficacy and safety of low molecular weight heparin (FAM) in the treatment of acute cerebral infarction (AIS). Methods: A randomized controlled study of 98 patients with AIS was enrolled. Among them, 56 cases were enamine and 42 cases were control. According to CSS, the neurological status of two groups of AIS patients before and after treatment were analyzed and compared, and the incidence of hemorrhagic complications and mortality were compared between the two groups. Results: The total effective rate of the group was better than that of the control group (P <0.05). In the vertebrobasilar artery (VBA) system, the Fuming group was superior to the control group, with significant differences in efficacy (P <0.255). In terms of safety, there was no significant difference between feminine and hemorrhagic comorbidity and mortality in the control group. Conclusion: Emin is safe and effective in treating VBA AIS.